Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey

Cicero, Arrigo Francesco Giuseppe; Salvetti, Massimo; Musumeci, Maria Beatrice; Ferrucci, Andrea; Borghi, Claudio; Volpe, Massimo

doi:10.1186/s40885-017-0066-0

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 Physician preference and patient comorbidity also affect the prescription of antihypertensive medications. [58][59][60][61] Intravenous hydralazine was more preferred in older women with chronic hypertension, whereas intravenous labetalol was more preferred in women with more severe phenotypes ( Table 2). Significant differences in characteristics between the groups may have posed bias in response interpretation.…”

Section: Discussionmentioning

confidence: 99%

Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women

Chera-aree

Tengtrakulcharoen

Leetheeragul

et al. 2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Response to acute treatment of severe hypertension during pregnancy in Asian women was not known. Labor and delivery checklists of Thai women treated with intravenous hydralazine or labetalol for systolic blood pressure (SBP) ≥ 160 or diastolic blood pressure (DBP) ≥ 110 mm Hg from January 2011 to December 2013 were reviewed as parts of an audit. Primary outcome was prompt achievement of SBP 140-150 and DBP 90-100 mm Hg after the first bolus. Secondary outcomes were medication-related undesired effects. The mean ± standard deviation age and prevalence of chronic hypertension in hydralazine (n = 62) versus labetalol (n = 64) groups were 32.5 ± 6 versus 29.9 ± 6.8 years and 50% versus 21.9%, respectively (P < .05). Magnesium sulfate was promptly administered on admission to every woman to prevent seizure. Targeted blood pressure was timely achieved in 41.9% and 67.2% of the hydralazine and labetalol groups, respectively (P < .05). Nonreassuring fetal heart rate occurred in 51.6% and 32.8% of the hydralazine and labetalol groups, respectively (P = .05). The prevalence of cesarean section and Apgar score < 7 were not significantly different (P > .05). Real-life clinical experiences suggested significant advantages of intravenous labetalol over hydralazine in pregnant women with severe hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women

Chera-aree

Tengtrakulcharoen

Leetheeragul

et al. 2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…As patient survival has improved, lifestyle modification and better supportive care have become equally important in PAH [55] as it is the case with other chronic diseases [56][57][58][59]. Lifestyle modification and supportive care have been overlooked in PAH because it has previously been considered untreatable.…”

Section: Lifestyle Modification and Better Sup-portive Carementioning

confidence: 99%

Current status of pulmonary arterial hypertension in Korea

Jang

Chung

2019

Korean J Intern Med

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is characterized by remodeling of the distal pulmonary arteries resulting in high pulmonary vascular resistance and, eventually, right ventricular heart failure. Although current advances in PAH therapy have improved outcomes, poor survival remains a reality worldwide, including Korea. One of the most important issues in PAH is the late diagnosis, since screening or diagnostic efforts are often overlooked due to the rarity of disease. Data from Korean registries and observational cohorts show that delayed detection leads to increased morbidity. Additionally, low percentages of Korean patients are committed to intensive PAH-targeted therapy. Current Korean health insurance policies’ lack of coverage for new PAH-targeted drugs and upfront combination therapy may also hamper the improvement of treatment outcomes. Understanding individual variability in response to therapeutics through deep phenotyping is a novel strategy that should be considered when treating PAH. Overall, early detection of PAH by proactive screening together with early, intensive, individualized PAH therapy using deep phenotyping is crucial for improving prognoses for PAH patients in Korea.

show abstract

“…Medical scientists in Russia and abroad pay special attention to etiology, pathophysiology, pathogenesis, diagnosis, treatment and prognosis of AH. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] The prevalence of AH among the adult population is from 30-45% up to 60% and it is more frequent among people over 60 years. 18,19 Throughout the world, AH also significantly affects cardiovascular complications and results in high death rate.…”

mentioning

confidence: 99%

Is relaxation exercise therapy effective in the management of patients with severe arterial hypertension?

Lebedeva

Achilov²,

Mavlyanova

et al. 2021

Eur J Transl Myol

View full text Add to dashboard Cite

Arterial hypertension (AH) is a burning problem in the world. Antihypertensive pharmacological therapy combined by physical exercises is well-studied in patients with mild and moderate AH. However, studies that have investigated relaxation in patients with severe AH in addition to drug therapy are lacking. Optimization of a comprehensive treatment for patients with severe AH, by using a multicomponent rational antihypertensive pharmacotherapy (PT) with subsequent application of relaxation exercise therapy (RET). The study involved 32 male patients with severe AH. Initially, clinical-instrumental and laboratory examination, blood pressure registration and daily arterial blood pressure monitoring were carried out. Suitable PT was selected for all the patients. 3 months after starting PT the patients were divided in 2 groups. The patients of the 1st group were prescribed RET in addition to PT. The 2nd group of patients continued receiving PT alone. 3 months later, average daily blood pressure (ADBP)-syst and ADBP-diast were compared in both groups. Three months after PT both groups demonstrated a significant decrease in ADBP-syst and ADBP diast, but these indicators remained higher than normal and did not reach the target level. Three months after the inclusion of RET in the comprehensive treatment, the 1st group demonstrated a significant decrease in ADBP (systolic and diastolic), not only in comparison with the initial data, but also with the data observed three months after PT. After 6 months, ADBP-syst and ADBP-diast in the 1st group were significantly lower compared with those of patients in the 2nd group. The inclusion of RET in addition to a multicomponent antihypertensive PT is a promising treatment option for severe AH.

show abstract

Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey

Cited by 5 publications

References 27 publications

Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women

Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women

Current status of pulmonary arterial hypertension in Korea

Is relaxation exercise therapy effective in the management of patients with severe arterial hypertension?

Contact Info

Product

Resources

About